Description

Elamipretide Triacetate is a mitochondria-targeted tetrapeptide that selectively targets cardiolipin on the inner mitochondrial membrane. By stabilizing cardiolipin and improving mitochondrial bioenergetics, Elamipretide helps reduce mitochondrial dysfunction and oxidative damage. This compound is widely studied in experimental models of mitochondrial diseases, cardiovascular disorders, neurodegeneration, and metabolic syndromes.

Elamipretide Triacetate holds promise in research focused on improving mitochondrial health and mitigating the effects of mitochondrial-related cellular damage.

Product Specifications

Mechanism of Action & Research Applications

Elamipretide Triacetate selectively binds to cardiolipin in the inner mitochondrial membrane, stabilizing it and improving mitochondrial electron transport chain efficiency. This results in enhanced ATP production and reduced production of reactive oxygen species (ROS). Through this mechanism, Elamipretide helps prevent mitochondrial swelling, oxidative stress, and apoptosis in damaged cells.

Research applications include:

• Studying mitochondrial dysfunction and bioenergetics

• Investigating treatments for mitochondrial myopathies and cardiomyopathies

• Exploring neurodegenerative disease mechanisms

• Evaluating oxidative stress and cellular aging pathways

Side Effects (For Research Context Only)

In laboratory research, Elamipretide Triacetate has demonstrated low toxicity and good mitochondrial protective effects. Side effects in humans are not applicable as it is strictly for experimental use.

Disclaimer

Elamipretide Triacetate is intended solely for laboratory research use and is not approved for clinical or therapeutic applications.